Cargando…
Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats
BACKGROUND: Mangiferin (MNG) is known to possess antidiabetic and antioxidant activity. However, there is no experimental evidence presently available in the literature with regard to its ameliorating effects on diabetes mellitus coexisting with metabolic syndrome. OBJECTIVE: The present study was d...
Autores principales: | Suman, Rajesh Kumar, Mohanty, Ipseeta Ray, Maheshwari, Ujwala, Borde, Manjusha K, Deshmukh, YA |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010077/ https://www.ncbi.nlm.nih.gov/pubmed/27621658 http://dx.doi.org/10.2147/DMSO.S109599 |
Ejemplares similares
-
Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome
por: Suman, Rajesh Kumar, et al.
Publicado: (2023) -
Antidiabetic activity of Commiphora mukul and Phyllanthus emblica and Computational analysis for the identification of active principles with dipeptidyl peptidase IV inhibitory activity
por: Mohanty, Ipseeta Ray, et al.
Publicado: (2021) -
Development of an Experimental Model of Diabetes Co-Existing with Metabolic Syndrome in Rats
por: Suman, Rajesh Kumar, et al.
Publicado: (2016) -
Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals
por: Davis, Joseph A., et al.
Publicado: (2010) -
Tackling dipeptidyl peptidase IV in neurological disorders
por: Al-Badri, Ghaith, et al.
Publicado: (2018)